LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

BACKGROUND: SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and is administered intramuscularly monthly or every 2 months by a healthcare provider. COVID-19 and the resultant restrictio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: D'Amico, Ronald, Benn, Paul, McCoig, Cynthia C, Griffith, Sandy, Hudson, Krischan J, Sutton, Kenneth, Harrington, Conn M, Wu, Sterling, Williams, Will, Hove, Kai S, Martin Espanol, Carlos, Fricker, E Jane, Patel, Parul, Margolis, David
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Late Breaker Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa515.1905
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados